Evidence map›Paper›PMID 14671650›Full record

ReviewLeukemia2003

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

J J M van Dongen, A W Langerak, M Brüggemann, P A S Evans, M Hummel, F L Lavender, E Delabesse, F Davi, E Schuuring, R García-Sanz and 12 more

Open access · greenAbstract readMulticenter StudyReview
PubMed Publisher
In one paragraph

Review in Leukemia, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,197 papers.

0numbers the graph read from it
0cells of the map it votes in
1,197citing papers in PubMed
54.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,197 citing papers in PubMed, 3,023 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Humoral immunity in cancer.Signal transduction and targeted therapy · 2026
    Review
  9. Article
  10. PAX1 and ZNF582 Methylation as a Triage Strategy in Cytologic and hrHPV+ Scrapings in Both Chinese and Dutch Cohorts.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,137 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 6 countries.

J J M van DongenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. j.j.m.vandongen@erasmusmc.nl
A W Langerak
M Brüggemann
P A S Evans
M Hummel
F L Lavender
E Delabesse
F Davi
E Schuuring
R García-Sanz
J H J M van Krieken
J Droese
D González
C Bastard
H E White
M Spaargaren
M González
A Parreira
J L Smith
G J Morgan
M Kneba
E A Macintyre
Complejo Hospitalario de Salamanca · ESUniversitäts Hautklinik Kiel · DEErasmus MC · NLHôpital Necker-Enfants Malades · FRUniversity of Leeds · GBAcademic Medical Center · NLCentre Henri BecquerelFreie Universität Berlin · DEIPO Porto · PTLeiden University Medical Center · NLRadboud University Nijmegen · NLSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes and the chromosome aberrations t(11;14) and t(14;18). This has resulted in 107 different primers in only 18 multiplex PCR tubes: three VH-JH, two DH-JH, two Ig kappa (IGK), one Ig lambda (IGL), three TCR beta (TCRB), two TCR gamma (TCRG), one TCR delta (TCRD), three BCL1-Ig heavy chain (IGH), and one BCL2-IGH. The PCR products of Ig/TCR genes can be analyzed for clonality assessment by heteroduplex analysis or GeneScanning. The detection rate of clonal rearrangements using the BIOMED-2 primer sets is unprecedentedly high. This is mainly based on the complementarity of the various BIOMED-2 tubes. In particular, combined application of IGH (VH-JH and DH-JH) and IGK tubes can detect virtually all clonal B-cell proliferations, even in B-cell malignancies with high levels of somatic mutations. The contribution of IGL gene rearrangements seems limited. Combined usage of the TCRB and TCRG tubes detects virtually all clonal T-cell populations, whereas the TCRD tube has added value in case of TCRgammadelta(+) T-cell proliferations. The BIOMED-2 multiplex tubes can now be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease.

Indexed as

Chromosome AberrationsClone CellsDNA PrimersEuropean UnionGene Rearrangement, T-LymphocyteHumansImmunoglobulinsLymphoproliferative DisordersNeoplasm, ResidualPolymerase Chain ReactionReceptors, Antigen, T-CellReference StandardsReproducibility of ResultsDNA PrimersImmunoglobulinsReceptors, Antigen, T-Cell

Identifiers

PMID14671650
OpenAlexW2020094108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.